Filtros de búsqueda

Lista de obras de

A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients

scientific article published on 03 April 2019

Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia

artículo científico publicado en 2021

Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia

scientific article published on 14 January 2019

Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Tria

artículo científico publicado en 2019

Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement

artículo científico publicado en 2018

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

artículo científico publicado en 2020

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

artículo científico publicado en 2017

Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians

artículo científico publicado en 2020

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines

artículo científico publicado en 2020

Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.

artículo científico publicado en 2018

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer

artículo científico publicado en 2018

Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results

artículo científico publicado en 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda